Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Tottori, Japan.
Department of Ophthalmology, Saneikai Tsukazaki Hospital, Hyogo, Japan.
Allergol Int. 2022 Oct;71(4):459-471. doi: 10.1016/j.alit.2022.07.005. Epub 2022 Sep 10.
Allergic conjunctival disease (ACD) is an inflammatory disease of the conjunctiva that is mainly caused by type I hypersensitivity response to allergens and accompanied by subjective symptoms and other findings induced by antigens. ACD is classified as allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. This article summarizes the third edition of the Japanese guidelines for allergic conjunctival diseases published in 2021 and outlines the diagnosis, pathogenesis, and treatment of ACD. Since the introduction of immunosuppressive eye drops, the treatment strategies for severe ACDs have significantly changed. To clarify the recommended standard treatment protocols for ACD, the advantages and disadvantages of these treatments were assessed using clinical questions, with a focus on the use of steroids and immunosuppressive drugs. This knowledge will assist healthcare providers and patients in taking an active role in medical decision making.
变应性结膜炎（ACD）是一种结膜炎症性疾病，主要由过敏原引起的 I 型超敏反应引起，伴有抗原诱导的主观症状和其他发现。ACD 分为过敏性结膜炎、特应性角结膜炎、春季角结膜炎和巨大乳头性结膜炎。本文总结了 2021 年发布的日本第三版变应性结膜炎指南，概述了 ACD 的诊断、发病机制和治疗。自免疫抑制眼药水问世以来，严重 ACD 的治疗策略发生了显著变化。为了明确 ACD 的推荐标准治疗方案，使用临床问题评估了这些治疗方法的优缺点，重点关注了类固醇和免疫抑制剂的使用。这些知识将有助于医疗保健提供者和患者积极参与医疗决策。
